Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release (pasireotide LAR) with octreotide long-acting repeatable (octreotide LAR) in managing carcinoid symptoms refractory to first-generation somatostatin analogues. Adults with carcinoid tumors of the digestive tr...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Drug Des Devel Ther
Main Authors: Wolin, Edward M, Jarzab, Barbara, Eriksson, Barbro, Walter, Thomas, Toumpanakis, Christos, Morse, Michael A, Tomassetti, Paola, Weber, Matthias M, Fogelman, David R, Ramage, John, Poon, Donald, Gadbaw, Brian, Li, Jiang, Pasieka, Janice L, Mahamat, Abakar, Swahn, Fredrik, Newell-Price, John, Mansoor, Wasat, Öberg, Kjell
Formato: Artigo
Idioma:Inglês
Publicado: Dove Medical Press 2015
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4562767/
https://ncbi.nlm.nih.gov/pubmed/26366058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S84177
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares